PsychoGenics leverages transgenic models to advance preclinical studies of amyotrophic lateral sclerosis (ALS), a progressive paralytic disorder characterized by motor neuron degeneration in the brain and spinal cord. Our expertise extends to both sporadic (SALS) and familial (FALS) forms of ALS, with a particular focus on mutations in the superoxide dismutase 1 (SOD1) and TDP-43.

Our Models for Preclinical ALS Studies

We utilize industry-leading transgenic models and extensive expertise in ALS research to drive your potential breakthrough:

This model is characterized by progressive decreases in body weight, grip strength, motor function, muscle action potential, and nerve conduction. These phenotypic changes provide valuable preclinical insights into ALS disease progression and therapeutic responses.

We characterized the ΔNLS8 inducible TDP43 mouse model of ALS. Upon withdrawal of doxycycline, these mice exhibit progressive motor impairment, muscle denervation, and motor neuron loss, closely resembling the disease pathology observed in ALS patients.

Multiple endpoints have been characterized in the model, including body weight, onset of tremor, clasping behavior, survival, compound muscle action potential (CMAP), gait analysis, and brain and CSF biomarkers (including inflammatory markers and NF-L).

Partnering for Preclinical ALS Research Breakthroughs

PsychoGenics actively collaborates with researchers, pharmaceutical companies, and foundations committed to ALS research. Our extensive experience and specialized models provide a comprehensive and tailored approach to the preclinical development of your novel ALS therapy. 

Collaborate with us to deepen our understanding of ALS pathogenesis and advance your therapeutic breakthrough, ultimately enhancing the lives of ALS patients worldwide.

Partner with PsychoGenics

and discover your next breakthrough

Get Started